Partnership to End Addiction

Anthem Blue Cross and Blue Shield Foundation Awards $11 Million to Community Partners in New York

Retrieved on: 
Friday, March 15, 2024
Women, Other Philanthropy, Seniors, Men, General Health, Consumer, Food, Beverage, People with Disabilities, Retail, Mental Health, Parenting, Baby, Maternity, Health Insurance, Fitness & Nutrition, LGBTQ+, Philanthropy, Alternative Medicine, Health, Fund Raising, Foundation, Vitamins, Supplements, Well, BIPOC, American Heart Association, Culture, Conditional sentence, Organization, Food bank, Risk, Diabetes, Suds, City, Mental health, FAM, Elevance Health, Pregnancy, Woman, Partnership to End Addiction, New Yorker, 2005 in television, Blue Shield, Maternal health, Addiction, Hypertension, MHA, Clifford Whittingham Beers, Pharmaceutical industry

Anthem Blue Cross and Blue Shield Foundation continued its critical work to measurably improve health and strengthen local communities in 2023.

Key Points: 
  • Anthem Blue Cross and Blue Shield Foundation continued its critical work to measurably improve health and strengthen local communities in 2023.
  • “Our Foundation strives to improve the health of humanity by addressing health inequities and strengthening our communities in New York.
  • Our strategy underscores this commitment by focusing on partnerships and programs that aid the health of the socially vulnerable,” said Victor DeStefano, President of Anthem Blue Cross and Blue Shield in New York.
  • Other Anthem Blue Cross and Blue Shield Foundation grant recipients last year included: American Heart Association, Project Renewal, Gay Men’s Health Crisis, Community Access, and Tent Ministries.

South Rampart Pharma to Participate in Upcoming Investor Events

Retrieved on: 
Tuesday, October 10, 2023
Shades of gray, BIO, Central nervous system, Liver, UCSF, Clinic, NINDS, University, Biological activity, Therapy, HEAL, Partnership to End Addiction, Mission, DSM-IV codes, Safety, Bangladesh Technical Education Board, Pain, National Institutes of Health, Conference, University of California, San Francisco, Entrepreneurship, NIH, Pharmaceutical industry

NEW ORLEANS, Oct. 10, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company's executive team will be participating in the upcoming investor events throughout October 2023:

Key Points: 
  • South Rampart's Co-founder and CEO, Dr. Hernan Bazan, will present a Corporate Overview followed by a questions and answers session.
  • Dr. Bazan's presentation will discuss SRP-001's unique mechanisms of action as well as Phase 1 clinical trial data.
  • In addition to the Corporate Overview, Dr. Bazan will be featured as a speaker on a panel exploring best practices for translation and commercialization of innovation spun out from academia.
  • 17th Annual Pain Therapeutics Summit (San Diego, CA):
    Title: "Transcriptomic Signature, Bioactivity and Safety of a Non-hepatoxic Novel Non-opioid Analgesic: From Discovery to the Clinic."

The Dallas Morning News Launches Transformative Series Examining Fentanyl’s Deadly Grip on North Texas

Retrieved on: 
Thursday, September 7, 2023
News, National Institute on Drug Abuse, University of Texas Health Science Center at San Antonio, Naloxone, Human services, DallasNews Corporation, Hope, Centers for Disease Control and Prevention, The Dallas Morning News, Heroin, Texas Health and Human Services Commission, Organization, School, Morphine, Text, Knowledge, Dallas, Partnership to End Addiction, Fentanyl, Pharmaceutical industry, DALLAS

DALLAS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- DallasNews Corporation (Nasdaq: DALN) -

Key Points: 
  • The potent synthetic opioid has been responsible for the overdose deaths of over 1,100 North Texans since 2021.
  • More than two dozen News staffers spent months researching, reporting, writing, editing, photographing and designing a wide-ranging package about the deadly drug.
  • “Deadly Fake: 30 Days Inside Fentanyl’s Grip on North Texas,” tells in heart-breaking and stark detail the rapidly growing crisis unfolding across the nation and at home.
  • North Texas Behavioral Health Authority: 24-hour crisis hotline at 1-866-260-8000 or ntbha.org .

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

Retrieved on: 
Tuesday, July 18, 2023
PK, Volunteering, Condition, NCT, Addiction, Initiative, Opioid use disorder, United States drug overdose death rates and totals over time, OTCQB, OUD, Trial of the century, Development, Plasma protein binding, Clinical trial, Patient, Partnership to End Addiction, Collection, Cooperative, NIDA, Pain management, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RFA, NIH, Food, Safety, Substance abuse, Pharmaceutical industry, Naltrexone, Drug overdose

Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.

Key Points: 
  • Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
  • Based on these results, we have submitted for fast track designation and we are preparing to also apply for expanded access.
  • Typically, the FDA responds to fast track designation requests within 60 days or less.
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

BioCorRx Provides Business Update for the First Quarter of 2023

Retrieved on: 
Tuesday, May 16, 2023
Volunteering, PK, Condition, NCT, Addiction, Initiative, Opioid use disorder, OTCQB, OUD, Trial of the century, Development, Clinical trial, Partnership to End Addiction, Risk, Cooperative, NIDA, Pain management, CFO, Security (finance), RFA, NIH, Safety, Substance abuse, Pharmaceutical industry, Naltrexone, Drug overdose

ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments.

Key Points: 
  • Notably, data showed that BICX104 was generally well-tolerated, with no serious adverse events, and provided subjects with 84 days of therapeutic levels of naltrexone.
  • This confirms our expectations that BICX104 naltrexone pellets can be safely administered without significant risk.
  • We hope to get both submitted in the second quarter of 2023 pending final preparation by our regulatory team.”
    “We saw an increase in revenue in the first quarter of 2023.
  • A copy of the Company’s quarterly report on Form 10-Q for the first quarter ended March 31, 2023 has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/ .

BioCorRx Provides Business Update for 2022

Retrieved on: 
Monday, April 3, 2023
Volunteering, PK, Private sector, Condition, NCT, Addiction, Expanded access, Initiative, Opioid use disorder, OTCQB, OUD, Veteran, Trial of the century, Plasma, Development, Clinical trial, Patient, Partnership to End Addiction, Cooperative, NIDA, Pain management, CFO, Security (finance), Substance abuse, FDA, Annual report, Factitious disorder, NIH, RFA, Safety, Pharmaceutical industry, Naltrexone, Drug overdose

ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “2022 was a transformative year for BioCorRx, as we made significant progress advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).
  • BICX104 was well tolerated with no serious adverse events reported and achieved 84 days of therapeutic naltrexone plasma concentrations.
  • “We saw an increase in revenue in 2022 due to the increased number of patients treated at licensed clinics.

BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data

Retrieved on: 
Thursday, February 23, 2023
Pain management, Development, National Institute on Drug Abuse, Safety, Volunteering, Cooperative, Partnership to End Addiction, Disorder, Clinical trial, Opioid use disorder, FDA, Trial of the century, Condition, OUD, NIH, NCT, RFA, Bangladesh Technical Education Board, NIDA, Addiction, CSO, PK, OTCQB, Initiative, Medical device, Pharmaceutical industry, Drug overdose, Naltrexone

The PK data indicate that BICX104 delivers up to 3 months of therapeutic levels, as desired.

Key Points: 
  • The PK data indicate that BICX104 delivers up to 3 months of therapeutic levels, as desired.
  • Additionally, and as previously announced ,  the study site has not observed any serious adverse events.
  • BICX104 is being developed through a cooperative agreement with the NIDA, part of the NIH, under award number UH3DA047925, funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative.
  • The NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis.